These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 37407698)

  • 1. Molecular mechanism of ensitrelvir inhibiting SARS-CoV-2 main protease and its variants.
    Lin M; Zeng X; Duan Y; Yang Z; Ma Y; Yang H; Yang X; Liu X
    Commun Biol; 2023 Jul; 6(1):694. PubMed ID: 37407698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
    Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
    Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir.
    Duan Y; Zhou H; Liu X; Iketani S; Lin M; Zhang X; Bian Q; Wang H; Sun H; Hong SJ; Culbertson B; Mohri H; Luck MI; Zhu Y; Liu X; Lu Y; Yang X; Yang K; Sabo Y; Chavez A; Goff SP; Rao Z; Ho DD; Yang H
    Nature; 2023 Oct; 622(7982):376-382. PubMed ID: 37696289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence of SARS-CoV-2 3CL protease mutations associated with nirmatrelvir or ensitrelvir resistance.
    Ip JD; Wing-Ho Chu A; Chan WM; Cheuk-Ying Leung R; Umer Abdullah SM; Sun Y; Kai-Wang To K
    EBioMedicine; 2023 May; 91():104559. PubMed ID: 37060743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the inhibition of coronaviral main proteases by ensitrelvir.
    Lin C; Jiang H; Li W; Zeng P; Zhou X; Zhang J; Li J
    Structure; 2023 Sep; 31(9):1016-1024.e3. PubMed ID: 37421945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly specific SARS-CoV-2 main protease (M
    Rauch S; Costacurta F; Schöppe H; Peng JY; Bante D; Erisoez EE; Sprenger B; He X; Moghadasi SA; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Wang D; Naschberger A; Dunzendorfer-Matt T; Kaserer T; von Laer D; Heilmann E
    Antiviral Res; 2024 Nov; 231():105969. PubMed ID: 39053514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ensitrelvir as a potential treatment for COVID-19.
    McCarthy MW
    Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
    Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
    J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies.
    Tan B; Joyce R; Tan H; Hu Y; Wang J
    Acc Chem Res; 2023 Jan; 56(2):157-168. PubMed ID: 36580641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantum Chemical Interaction Analysis between SARS-CoV-2 Main Protease and Ensitrelvir Compared with Its Initial Screening Hit.
    Watanabe C; Tanaka S; Okiyama Y; Yuki H; Ohyama T; Kamisaka K; Takaya D; Fukuzawa K; Honma T
    J Phys Chem Lett; 2023 Apr; 14(15):3609-3620. PubMed ID: 37023394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
    Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
    Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
    Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
    Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332.
    Li J; Lin C; Zhou X; Zhong F; Zeng P; Yang Y; Zhang Y; Yu B; Fan X; McCormick PJ; Fu R; Fu Y; Jiang H; Zhang J
    J Virol; 2022 Apr; 96(8):e0201321. PubMed ID: 35389231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comprehensive study of SARS-CoV-2 main protease (M
    Costacurta F; Dodaro A; Bante D; Schöppe H; Sprenger B; Moghadasi SA; Fleischmann J; Pavan M; Bassani D; Menin S; Rauch S; Krismer L; Sauerwein A; Heberle A; Rabensteiner T; Ho J; Harris RS; Stefan E; Schneider R; Kaserer T; Moro S; von Laer D; Heilmann E
    bioRxiv; 2023 Oct; ():. PubMed ID: 37808638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ensitrelvir Fumaric Acid: First Approval.
    Syed YY
    Drugs; 2024 Jun; 84(6):721-728. PubMed ID: 38795314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.